Author: Taurus

FDA opens path to TRT for low libido in idiopathic hypogonadism

Posted on by Taurus

FDA opens path to TRT for low libido in idiopathic hypogonadism

The FDA is open to reviewing TRT for low libido in men with idiopathic hypogonadism, but no products are approved yet. See potential eligibility and key safety considerations.

Estimated reading time: 8 minutes

Key takeaways

  • The FDA invited supplemental applications to evaluate TRT for treating low libido in men with idiopathic hypogonadism—no approvals yet.
  • This does not extend to age-related testosterone decline; existing indications remain unchanged.
  • Safety signals (blood pressure increases, erythrocytosis, atrial fibrillation, AKI, pulmonary embolism) keep monitoring central to care.
  • Potential future labels would likely require strict diagnostic criteria, symptom documentation, and ongoing follow-up.
  • Manufacturers have been asked to align with the FDA on evidence requirements in 2026 before any label changes.

Table of contents

  1. What exactly did the FDA announce?
  2. Idiopathic hypogonadism vs. age-related low testosterone
  3. Why now? The evidence the FDA considered
  4. What hasn’t changed
  5. If approved, who might qualify?
  6. Practical implications for patients now
  7. Safety, monitoring, and known risks
  8. What sponsors must prove next
  9. Why this matters for the TRT community
  10. How Taurus Meds can support patients
  11. The bottom line

What exactly did the FDA announce?

On April 16, 2026, the FDA said it is open to reviewing supplemental NDAs for a new TRT indication: treatment of low libido in men with idiopathic hypogonadism. The agency’s statement follows review of published trials and discussions at a December 2025 expert panel. Importantly:

  • No TRT product has been approved for this new indication yet.
  • The FDA is asking companies to meet with the agency and present robust safety and efficacy data tailored to this patient group.
  • Existing approvals—primarily for hypogonadism due to structural or genetic causes—remain unchanged.

In effect, the FDA is signaling that evidence to date may justify a narrow, symptom-targeted expansion (low libido) in a specific diagnosis (idiopathic hypogonadism), if manufacturers can meet the statutory bar for substantial evidence.

Idiopathic hypogonadism vs. age-related low testosterone

Clear definitions matter for patients, clinicians, and insurers. The FDA’s position focuses on idiopathic hypogonadism—not age-related testosterone decline.

  • Idiopathic hypogonadism: Low testosterone with symptoms and no identifiable cause after appropriate evaluation. Men may have persistent low total testosterone (often defined as <300 ng/dL on repeat morning testing) and symptoms like low sexual desire, yet lack structural pituitary/testicular disease or reversible causes (medications, obesity-related suppression, acute illness). The “idiopathic” label implies careful exclusion of known drivers.
  • Structural or genetic hypogonadism: Longstanding approved indication. Examples include congenital forms (e.g., Klinefelter syndrome) or acquired damage to the testes or pituitary.
  • Age-related testosterone decline: Common with aging and multiple comorbidities but remains outside current FDA-supported indications for TRT.

The FDA’s new openness is deliberately narrow. It centers on a functional symptom—low libido—within idiopathic hypogonadism, where some trials suggest TRT can normalize testosterone and improve sexual desire.

Why now? The evidence the FDA considered

  • Restoring testosterone levels: Across FDA-approved products for established hypogonadism (e.g., Xyosted, Kyzatrex, Tlando), consistent pharmacokinetics and safety profiles show that TRT can reliably bring average serum testosterone back into a eugonadal range (roughly 300–1000 ng/dL), aligning with prior regulatory standards on exposure and consistency.
  • TRAVERSE trial safety: In hypogonadal men at elevated cardiovascular risk, TRT was non-inferior to placebo for major adverse cardiovascular events (MACE) with a hazard ratio of 0.96 (95% CI 0.78–1.17). While reassuring for MACE, the trial reported higher rates of certain adverse events in the TRT arm, including atrial fibrillation, acute kidney injury, and pulmonary embolism—warranting continued vigilance.
  • Postmarket safety updates: The FDA emphasizes class-wide risks, including increases in blood pressure (class warning updated in 2025), erythrocytosis, potential effects on the prostate, possible worsening of sleep apnea, and observational links to early venous thromboembolism risk.

Together, this body of evidence appears sufficient, in the FDA’s view, to justify evaluating sNDAs for low libido in idiopathic hypogonadism—but it does not replace the rigorous, product-specific data required before granting any label change.

What hasn’t changed

  • No immediate access change: Clinicians cannot prescribe TRT “on-label” for low libido in idiopathic hypogonadism until specific products are approved.
  • Age-related low T remains excluded: The FDA is not endorsing TRT for typical, age-related testosterone decline or general well-being.
  • Risk profile remains central: Monitoring for blood pressure, hematocrit, and prostate health remains standard for any TRT use.

If approved, who might qualify?

If sponsors submit convincing sNDAs and the FDA grants approvals, candidates would likely be:

  • Men with clearly documented low testosterone on repeat morning testing (commonly <300 ng/dL) plus persistent low sexual desire.
  • Those with appropriate evaluation excluding structural, genetic, or reversible causes (e.g., hyperprolactinemia, pituitary disease, testicular injury, medication effects, significant systemic illness).
  • Individuals assessed for cardiovascular risk, sleep apnea, polycythemia risk, and prostate health before and during therapy.

Even with a new label, access will likely depend on careful diagnosis and monitoring to ensure benefits outweigh risks.

Practical implications for patients now

  • If you are exploring TRT for low libido: Certain products could eventually carry a label for low libido in idiopathic hypogonadism. For now, seek a thorough evaluation and discuss all options.
  • If you’re already on TRT: Your labeled indication does not change. Continue routine monitoring (blood pressure, hematocrit/hemoglobin, PSA as appropriate) and report new symptoms such as leg swelling, chest pain, shortness of breath, irregular heartbeat, or worsening sleep apnea.
  • If you have low testosterone but no clear cause: A precise workup is essential. Future labels will likely hinge on documentation of persistent low testosterone, relevant symptoms, and exclusion of known causes.
  • Insurance and coverage: A new indication could improve coverage pathways for this subset of men, though payer policies vary and may lag regulatory updates.

Safety, monitoring, and known risks

TRT’s benefits must be balanced with well-characterized risks. The FDA highlights:

  • Blood pressure increases: Monitor and manage blood pressure, especially in men with hypertension or cardiovascular risk.
  • Erythrocytosis: Periodic labs are standard; dose adjustments or pauses may be needed if hematocrit rises too high.
  • Cardiovascular signals beyond MACE: Higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism were noted in some analyses; weigh individual risk factors.
  • Prostate considerations: Monitor lower urinary tract symptoms and consider PSA testing as clinically indicated.
  • Sleep apnea: Symptoms can worsen; evaluate and treat as appropriate.
  • Fertility: Exogenous testosterone can suppress spermatogenesis; discuss alternatives if pursuing fertility.

What sponsors must prove next

  • Clear diagnostic criteria: Confirm patients truly had idiopathic hypogonadism, not age-related decline or reversible causes.
  • Clinically meaningful endpoints: Validated measures of sexual desire/libido demonstrating consistent improvement over placebo.
  • Longitudinal safety: Adequate data on cardiovascular, thrombotic, renal, hematologic, and prostate-related risks, including early risk windows.
  • Generalizability and subgroups: Clarity across age bands, baseline cardiovascular risk, and comorbidities.

The FDA has asked companies to align on data needs by April 30, 2026—signaling high regulatory rigor.

Why this matters for the TRT community

For years, patients and clinicians have navigated a gray zone: men with clear symptoms and low testosterone who do not fit neatly into structural or genetic categories. The April 2026 communication suggests the FDA sees enough maturing evidence—particularly for low libido—to consider a narrower, symptom-anchored indication under idiopathic hypogonadism.

This is not a blanket endorsement of TRT for all symptomatic, low-normal, or age-related cases. Rather, it is a potential path to bring on-label clarity to a subset of men who may benefit when carefully selected, counseled, and monitored.

How Taurus Meds can support patients

  • Education first: We help patients understand the difference between idiopathic and age-related hypogonadism and what the FDA’s evolving position may mean.
  • Thoughtful evaluation: We work with clinicians who follow evidence-based diagnostic pathways and monitoring standards, including blood pressure, hematocrit, and prostate health where appropriate.
  • Ongoing updates: As sponsors engage with the FDA and data requirements come into focus, we will keep our community informed about timelines, results, and any approved label changes.

Our goal is to combine access with safety—ensuring the right patients receive the right therapy with the right oversight.

The bottom line

The FDA’s 2026 announcement on TRT for low libido in idiopathic hypogonadism is a careful, science-led opening—not an approval. It acknowledges maturing evidence, including reassuring MACE results from TRAVERSE alongside important safety signals. If manufacturers deliver strong data, men with well-documented idiopathic hypogonadism and persistent low libido could see clearer on-label treatment options.

Until then, daily practice remains unchanged. Thoughtful evaluation, shared decision-making, and diligent monitoring are essential. For patients, the message is cautiously optimistic: evidence is moving, regulators are listening, and clarity may be coming—if new data confirm that benefits meaningfully outweigh risks in the right patients.

Disclaimer

This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication without consulting a qualified healthcare professional.

Sources

TRT After Ischemic Stroke in Men With Type 2 Diabetes Safety and Mobility

Posted on by Taurus

TRT After Ischemic Stroke in Men With Type 2 Diabetes: Safety Signals and Mobility Clues From a Small but Notable Study

Estimated reading time: 9 minutes

Key takeaways

  • In a small post-stroke cohort (Morgunov 2018), hypogonadism was prevalent, and TRT with testosterone undecanoate (TU) correlated with mobility and quality-of-life gains over 2–5 years; the nonrandomized design limits causal inference.
  • Contemporary randomized data show no clear increase in nonfatal stroke with TRT over ~2 years, but higher rates of certain non–major adverse events (atrial fibrillation, acute kidney injury, pulmonary embolism) were noted.
  • In 2025, the FDA removed the boxed warning for major cardiovascular events from TRT labeling and added a class-wide warning that TRT can increase blood pressure.
  • In hypogonadal men with T2DM, some trials report improved insulin resistance and metabolic markers with TRT, warranting careful monitoring of blood pressure, hematocrit, and prostate parameters.
  • After ischemic stroke, shared decision-making and structured follow-up across endocrinology, neurology, and cardiology are essential when considering TRT.

Table of contents

  1. Why testosterone matters after stroke—especially with T2DM
  2. What Morgunov 2018 found in hypogonadal men after ischemic stroke
  3. Putting Morgunov into context: What do we know about TRT stroke risk?
  4. 2025 FDA label changes: A clearer, still-cautious safety picture
  5. What about metabolic benefits in T2DM?
  6. Considering TRT after stroke in T2DM: Practical, safety-first themes
  7. Open questions
  8. How Taurus Meds can help
  9. Conclusion
  10. Disclaimer
  11. Sources

Men navigating recovery after an ischemic stroke often discover another challenge hiding in plain sight: low testosterone. For men with type 2 diabetes (T2DM), hypogonadism is even more common—and it may influence how well recovery proceeds. One small observational study suggests testosterone replacement therapy (TRT) with testosterone undecanoate (TU) might support mobility and quality of life after stroke in hypogonadal men. At the same time, larger modern trials and updated FDA labeling remind us to weigh TRT stroke risk and cardiovascular safety signals with care.

This article reviews the Morgunov 2018 cohort, places it in context with broader testosterone–cardiometabolic evidence, and outlines practical considerations for men and clinicians considering TRT after stroke in the setting of T2DM.

Why testosterone matters after stroke—especially with T2DM

Low testosterone is common in men with T2DM and has been linked to reduced lean mass, lower exercise capacity, higher visceral fat, and mood changes. After an ischemic stroke, these factors can compound challenges with rehabilitation, balance, endurance, and motivation. Observational work also suggests that lower testosterone measured during or shortly after an ischemic stroke correlates with worse functional outcomes in the months that follow.

The Morgunov 2018 cohort found hypogonadism in roughly two-thirds of men evaluated after ischemic stroke, with a substantial proportion of hypogonadal cases occurring in men with T2DM. Those findings support what many clinicians see in practice: metabolic disease and neurovascular events often travel together, and androgen deficiency is frequently part of the picture.

What Morgunov 2018 found in hypogonadal men after ischemic stroke

Design at a glance

  • Population: Men recovering from ischemic stroke; 94 were followed.
  • Prevalence: Hypogonadism was identified in ~66% of the cohort overall, with many cases among those with T2DM.
  • Intervention: Injectable testosterone undecanoate (TU) for hypogonadal men; follow-up at 2 and 5 years.
  • Outcomes: Improvements in biochemical (testosterone levels), physical (mobility measures), and mental/quality-of-life parameters were reported in the TRT group.

What this suggests

  • Mobility and independence: TU-based TRT was associated with better mobility and functional markers over time, an outcome that resonates with rehabilitation goals after stroke.
  • Quality of life: Improvements in mood and self-reported well-being were described—potentially important drivers of engagement in rehab and physical activity.
  • Ischemic events: The authors proposed that testosterone deficiency may contribute to ischemic risk and that long-term TRT could support recovery; however, this inference is hypothesis-generating.

Critical limitations

  • Not randomized; no placebo control.
  • Potential selection and survivorship bias.
  • Modest sample size; single-country experience.
  • Not powered to robustly evaluate recurrent stroke or rare adverse events.

Bottom line on Morgunov: It is an intriguing signal—particularly for mobility and quality-of-life outcomes in hypogonadal men with T2DM after stroke—but not definitive evidence. It sets the stage for the key clinical question: can TRT be offered safely to the right post-stroke patient, and under what monitoring framework?

Putting Morgunov into context: What do we know about TRT stroke risk?

Evidence on TRT and cardiovascular events has evolved. Earlier retrospective studies raised concerns about composite risks of mortality, myocardial infarction, and stroke in some populations, while others suggested lower event rates when testosterone was normalized. A 2024 narrative review summarized the conflicting landscape and highlighted that study design, patient selection, and whether testosterone levels were actually restored are crucial variables.

The most consequential update comes from more recent, larger randomized data in men at high cardiovascular risk:

  • Noninferiority for MACE, neutral for stroke: A major cardiovascular-outcomes trial reported that TRT did not increase major adverse cardiovascular events compared to placebo over a median follow-up of about two years, and no signal emerged for increased nonfatal stroke.
  • Non-MACE safety signals: The same program found higher rates of certain non-MACE outcomes—atrial fibrillation (AF), acute kidney injury (AKI), and pulmonary embolism (PE)—in the TRT arm. These findings matter in a post-stroke population, where AF can complicate secondary prevention and PE/VTE risk is already a consideration.

What this means for TRT ischemic safety

  • Stroke specifically: Current high-quality evidence suggests no clear excess in nonfatal stroke with TRT over roughly two years in high-CV-risk men.
  • Broader vascular risk: Caution remains appropriate due to AF, AKI, and PE signals, and because some observational analyses have noted a transient early increase in venous thromboembolism shortly after starting TRT.
  • Individual risk varies: Baseline cardiovascular status, mobility limitations, hydration status, and use of anticoagulation or antiplatelet therapy may modify individual risk.

2025 FDA label changes: A clearer, still-cautious safety picture

In February 2025, the FDA made two notable updates for all testosterone products:

  • Removed: The boxed warning for major adverse cardiovascular events (reflecting noninferiority for MACE in a large outcomes study).
  • Added: A class-wide warning that TRT can raise blood pressure. This stems from ambulatory blood pressure monitoring data, especially with oral testosterone undecanoate formulations approved in recent years.

Practical implications

  • Blood pressure: Even modest, sustained increases in BP can matter after stroke. Clinicians often assess baseline BP carefully and track it during titration and maintenance.
  • Formulation choice: While the BP warning is class-wide, the BP signal was most clearly characterized in the context of oral TU; injectable and transdermal preparations may have different pharmacokinetics and monitoring considerations.

What about metabolic benefits in T2DM?

Several trials in hypogonadal men with T2DM or metabolic syndrome report improved insulin resistance and some favorable shifts in glycemic and lipid parameters with TRT. For example, a 12‑month transdermal study documented reductions in HOMA-IR and improvements in components of metabolic control compared with placebo, without a significant difference in serious adverse events.

How this matters post-stroke:

  • Improved metabolic health may indirectly support rehabilitation by enhancing energy levels, lean mass, and readiness for physical therapy.
  • Not all studies agree, and glycemic responses can differ by baseline status and adherence. Continuous diabetes care and lifestyle measures remain foundational whether or not TRT is used.

Considering TRT after stroke in T2DM: Practical, safety-first themes

  • Confirmation of hypogonadism
    • Diagnosis typically requires both symptoms and consistently low morning testosterone on two separate days.
    • Secondary causes (acute illness effects, certain medications, sleep disorders, pituitary disease) are considered before initiating therapy.
  • Timing relative to stroke
    • Many interventional studies exclude men with a very recent stroke, and timing is individualized. Stabilization of cardiovascular status and blood pressure usually precedes any decision about hormone therapy.
  • Formulation and goals
    • Injectable testosterone undecanoate (as used in Morgunov) offers infrequent dosing and stable levels for many patients. Transdermal formulations provide dose-adjustability and easier reversal if needed.
    • Goals often include symptom relief, functional gains (mobility, endurance), and metabolic support—balanced against cardiovascular, hematologic, and prostate safety.
  • Monitoring and risk mitigation
    • Blood pressure: The class-wide FDA warning makes routine BP tracking central, particularly early after initiation and with dose changes.
    • Hematocrit: TRT can raise red blood cell mass (erythrocytosis), which can thicken blood and potentially elevate thrombotic risk; clinicians generally monitor hematocrit and adjust therapy if it rises too high.
    • Prostate: Baseline PSA and ongoing assessment are common in age-appropriate men, with attention to urinary symptoms and shared decision-making around prostate cancer screening.
    • Cardiometabolic profile: Lipids, glycemic measures, weight, and symptom diaries can help tie treatment decisions to real-world function and quality of life.
    • Rhythm and thromboembolic risk: Given AF and PE signals in large trials, attention to arrhythmia symptoms, mobility plans, hydration, and VTE history is prudent. Coordination with neurology and cardiology can align TRT decisions with secondary stroke prevention.
  • Who may not be a good candidate
    • Men with uncontrolled hypertension, very high hematocrit, active or high-risk prostate cancer, or recent thromboembolic events are often deferred or managed with extreme caution.
    • Fertility plans matter: exogenous testosterone suppresses sperm production and is not a fertility therapy.
  • Setting expectations
    • Benefits, when they occur, are typically gradual. Mobility and quality-of-life gains—like those suggested by Morgunov—are best pursued alongside structured rehabilitation, nutrition, sleep optimization, and diabetes control.

Open questions

  • Can randomized trials in post-stroke hypogonadal men with T2DM confirm the mobility and quality-of-life gains suggested by Morgunov?
  • What is the optimal timing to initiate TRT after ischemic stroke, and what monitoring cadence best balances symptom relief with cardiovascular safety?
  • How do different TRT formulations compare on BP effects, erythrocytosis risk, and adherence in a post-stroke population?
  • How do modern diabetes therapies (e.g., GLP-1 RAs, SGLT2 inhibitors) interact with TRT on mobility, body composition, and vascular outcomes?

How Taurus Meds can help

  • Evidence-grounded counseling on TRT stroke risk and cardiometabolic trade-offs.
  • Coordination across endocrinology, neurology, cardiology, and primary care to align TRT with secondary stroke prevention plans.
  • Practical monitoring pathways for blood pressure, hematocrit, and prostate parameters, tailored to the chosen formulation.
  • Ongoing symptom and function tracking—so therapy remains tied to goals that matter: mobility, energy, and quality of life.

Conclusion

For hypogonadal men with T2DM recovering from ischemic stroke, the Morgunov 2018 cohort offers a cautiously optimistic signal: TRT with TU was associated with improved mobility and quality-of-life measures over years of follow-up. Larger, contemporary trials suggest no clear increase in nonfatal stroke with TRT, although non-MACE signals (AF, AKI, PE) and a class-wide FDA warning about blood pressure underscore the need for careful selection and monitoring.

The path forward is individualized. When hypogonadism is confirmed and symptoms are meaningful, a structured, team-based approach can responsibly test whether TRT helps—anchored in blood pressure vigilance, hematologic and prostate safety checks, and clear functional goals. Until dedicated randomized trials in post-stroke T2DM populations are completed, shared decision-making remains the best compass.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about testosterone therapy should be made with a qualified clinician who can assess individual risks and benefits.

Sources

TRT and Atrial Fibrillation Risk What TRAVERSE Means for Monitoring

Posted on by Taurus

TRT and Atrial Fibrillation Risk What TRAVERSE Means for Monitoring

Estimated reading time: ~10 minutes

Key takeaways

  • TRAVERSE found more atrial fibrillation with TRT (3.5%) vs placebo (2.4%) while MACE did not increase; deaths were numerically lower with TRT.
  • The AF signal was a secondary finding with important limitations; a 2025 observational analysis did not confirm a statistically significant AF increase.
  • In February 2025, the FDA removed the boxed MACE warning and added a class-wide blood pressure warning, emphasizing ambulatory BP monitoring (ABPM).
  • Early, individualized monitoring can mitigate non-MACE risks like AF and acute kidney injury (AKI), especially in higher-risk men.
  • Physiologic dosing and avoiding supraphysiologic peaks are linked with better outcomes; VA data associate normalized testosterone with lower AF incidence.

Contents

  1. Introduction
  2. What TRAVERSE actually found
  3. How strong is the AF signal?
  4. What newer data say
  5. The 2025 FDA label update
  6. Practical risk stratification before starting TRT
  7. Monitoring that matches the evidence
  8. The early months: why AF might appear—and how to reduce risk
  9. If you’re already on TRT
  10. Men with prior AF or higher cardiovascular risk
  11. What this means for safety—and for you
  12. Open questions we’re watching
  13. Conclusion

Introduction

Testosterone replacement therapy (TRT) has long carried debate around cardiovascular safety. The 2023 TRAVERSE trial added a new wrinkle: a higher rate of atrial fibrillation (AF) in men assigned to TRT compared with placebo, even as major adverse cardiovascular events (MACE) did not increase. In 2025, the FDA removed the boxed warning for MACE across testosterone products, while adding a class-wide warning about increases in blood pressure—shifting the focus from broad cardiovascular risk to targeted monitoring. Here’s what the latest evidence means if you’re considering TRT, already on therapy, or supporting someone who is.

What TRAVERSE actually found

TRAVERSE was a large, randomized, placebo-controlled trial enrolling 5,246 symptomatic men aged 45–80 with confirmed hypogonadism and preexisting or high cardiovascular risk. Over a median of 33 months:

  • MACE (cardiovascular death, nonfatal MI, nonfatal stroke) was not increased with TRT—the primary safety endpoint was met.
  • TRT recipients experienced more atrial fibrillation: 91 cases (3.5%) vs 63 (2.4%) with placebo (p=0.02).
  • Non-fatal arrhythmias overall were more frequent (p=0.001).
  • AKI occurred more often (60 vs 40 cases; p=0.04).
  • Pulmonary embolism events were numerically higher (0.9% vs 0.5%).
  • Paradoxically, there were 16 fewer deaths in the TRT group, a reassuring if exploratory signal.

This pattern reframes risk: while catastrophic endpoints were not elevated, certain non-MACE events—AF, AKI, and perhaps thromboembolism—merit attention during treatment, especially early on.

How strong is the AF signal?

Important context tempers the AF finding:

  • AF was a secondary outcome without mandated baseline ECGs or protocol-driven rhythm monitoring. Events relied on clinical diagnoses, which can vary in detection and documentation.
  • The study population skewed older with substantial cardiovascular comorbidity—men who already carry higher baseline AF risk.
  • Investigators and commentators have raised the “early mobilization” hypothesis: previously under-active, frail men may abruptly increase activity after TRT initiation (improved energy and anemia correction), transiently unmasking AF before longer-term cardiovascular gains accrue.
  • TRAVERSE did not provide dose-stratified AF analyses, so we cannot link events to supraphysiologic peaks or suboptimal titration.

Bottom line: the AF signal is real in this trial but methodologically limited and may not generalize to younger, lower-risk men or to care settings with tight dose control and proactive monitoring.

What newer data say

Since TRAVERSE, two complementary evidence streams inform interpretation:

  • A 2025 retrospective analysis found an increased risk of AKI with TRT (RR 1.53, 95% CI 1.07–2.18) but did not confirm a statistically significant AF increase (RR 1.48, 95% CI 0.93–2.37). While observational and confounded by design, it suggests AF risk may not be uniform across populations or practice styles.
  • Longitudinal observational data from the Veterans Affairs system indicated AF incidence was lowest in men whose testosterone was normalized to physiologic levels on TRT, compared with men whose levels were not normalized or who remained untreated. This aligns with clinical experience that careful titration and stable physiologic dosing correlate with better rhythm and vascular outcomes.

TRAVERSE also documented correction of anemia in many TRT recipients. Anemia is a recognized cardiovascular risk factor; its improvement could contribute to longer-term benefit that isn’t immediately visible in early safety signals.

The 2025 FDA label update: from broad warnings to targeted monitoring

In February 2025, the FDA removed the boxed warning about MACE from testosterone product labels and added a class-wide warning for increases in blood pressure based on ambulatory blood pressure monitoring data. The shift emphasizes:

  • No demonstrable increase in MACE when TRT is used as indicated in appropriately selected men.
  • Focused vigilance for non-MACE signals—especially blood pressure, arrhythmias, kidney function, and thromboembolic symptoms.
  • The practical value of ABPM and structured follow-up to catch manageable changes before they escalate.

Practical risk stratification before starting TRT

No article can assess your personal risk; that’s the role of your clinician. Still, it helps to understand how many practices approach stratification.

Factors that generally raise baseline AF or complication risk:

  • Prior AF or atrial flutter; known structural heart disease
  • Hypertension, obesity, diabetes, sleep apnea, thyroid disease
  • Chronic kidney disease or borderline renal function
  • Elevated hematocrit at baseline or prior erythrocytosis on TRT
  • Active smoking, heavy alcohol use, stimulant use
  • Age 65+ with multiple cardiovascular comorbidities

Reasonable baseline evaluations to discuss with your care team:

  • Confirmation of biochemical hypogonadism with morning testosterone on two days
  • Cardiovascular review, blood pressure measurement or ABPM
  • Hematocrit/hemoglobin, creatinine/eGFR, electrolytes
  • Consider a baseline ECG if arrhythmia risk is elevated or symptoms suggest palpitations; targeted cardiac evaluation as indicated
  • Sleep apnea screening if snoring, daytime sleepiness, or high STOP-BANG score

At Taurus Meds, we prioritize physiologic dosing and evidence-based monitoring tailored to a patient’s risk profile—particularly in the first few months when most non-MACE signals surface.

Monitoring that matches the evidence

Although schedules vary, the data and FDA update point to a few themes that many clinicians adopt:

  • Blood pressure: Incorporate ABPM or home BP checks, especially during dose titration and after any formulation change.
  • Serum testosterone: Monitor to maintain levels in the mid-normal physiologic range for age; avoid supraphysiologic peaks.
  • Hematocrit: Check periodically; address rising levels promptly to minimize thrombotic risk.
  • Renal function: Reassess creatinine/eGFR after initiation and with dose changes, particularly in men with preexisting kidney risk.
  • Symptoms review: Ask about palpitations, rapid or irregular heartbeat, dizziness, chest discomfort, decreased urine output, leg swelling, or sudden shortness of breath.

Cleveland Clinic authors have noted that outcomes depend on indication-based prescribing and vigilant monitoring to avoid excessive dosing—something that may not be consistently practiced in all settings. If care is fragmented, advocate for a clear follow-up plan.

The early months: why AF might appear—and how to reduce risk

If AF events cluster early, several modifiable factors may help reduce risk:

  • Gradual activity ramp-up: Rising energy is a common early benefit; a measured increase in physical activity may be safer than an abrupt jump from sedentary to vigorous exercise in men with underlying heart disease.
  • Dose and formulation: Avoid supraphysiologic peaks. Discuss whether your formulation’s pharmacokinetics align with stable levels for you.
  • Blood pressure and volume status: Monitor BP closely; manage salt intake prudently; maintain hydration, particularly with exercise or heat exposure.
  • Sleep and alcohol: Treat sleep apnea when present; moderate alcohol and avoid binge drinking, which can precipitate AF.
  • Interacting substances: Review decongestants, stimulants, and supplements with your clinician.

These are not substitutes for medical care but practical levers that, combined with individualized follow-up, may blunt early arrhythmia risk.

If you’re already on TRT

  • Do not stop therapy abruptly without talking to your prescriber. Sudden changes can cause symptom rebound and complicate evaluation.
  • Report new palpitations, irregular heartbeat, chest discomfort, shortness of breath, lightheadedness, decreased urination, or leg swelling promptly.
  • Keep lab and monitoring appointments. Dose adjustment to maintain physiologic levels is a safety feature, not merely a “check-the-box” task.
  • Share any ER or urgent care visits with your TRT clinician so findings (e.g., ECGs) inform your ongoing plan.

Men with prior AF or higher cardiovascular risk

TRAVERSE included men at elevated cardiovascular risk, and still showed no increase in MACE. However, for those with established AF, heart failure, advanced kidney disease, or multiple risk factors, conversations typically include:

  • Cardiology co-management, especially if AF has been symptomatic or difficult to control
  • Baseline ECG and, when indicated, rhythm monitoring
  • Early and more frequent follow-up during the first 3–6 months
  • Clear thresholds for contacting the care team if symptoms arise

TRT may still be appropriate in select patients when hypogonadism is confirmed and benefits justify risks; this is a nuanced, shared decision-making process.

What this means for safety—and for you

The weight of evidence now supports a refined message:

  • When TRT is prescribed for true hypogonadism and carefully titrated, MACE does not appear elevated, which the FDA recognized by removing the boxed warning.
  • Non-MACE safety signals—including AF, AKI, and potential thromboembolism—are real but manageable with patient selection, physiologic dosing, and proactive surveillance.
  • Long-term, steady, physiologic testosterone levels may even relate to lower AF incidence in real-world cohorts, underscoring the value of dose control and adherence.

For men exploring TRT, the practical question is less “Is TRT categorically safe or unsafe?” and more “What is my individual risk, and how will my care team monitor and mitigate it—especially early on?”

At Taurus Meds, we approach TRT as a longitudinal partnership: confirm the diagnosis, personalize dosing to physiologic targets, use ABPM and lab monitoring where it adds value, and keep communication open if symptoms evolve.

Open questions we’re watching

  • Mechanism: Why did TRAVERSE show more AF while normalized testosterone in observational data corresponded to less AF? Is early unmasking the key, or is there a biological threshold effect?
  • Early vs. long-term risk: What intensity and duration of early monitoring best minimize AF and AKI without overburdening patients?
  • Dose-response: Which serum levels or pharmacokinetic patterns best separate benefit from risk in diverse populations?
  • Real-world practice: How often are indication-based prescribing and titration achieved outside of clinical trials?
  • Subgroups: Which baseline characteristics most strongly predict secondary safety signals, and can we tailor follow-up accordingly?
  • AKI and PE: What are the dominant mechanisms, and how reversible are these events with dose adjustment or discontinuation?

Conclusion

TRAVERSE reshaped the conversation: MACE risk is not the main barrier to TRT for appropriately selected men, but non-MACE events—especially AF and AKI—deserve targeted, early vigilance. The 2025 FDA label update aligns with this nuance, emphasizing blood pressure monitoring and individualized follow-up rather than blanket warnings.

For patients and clinicians, the path forward is practical: confirm true hypogonadism, stratify risk thoughtfully, titrate to physiologic levels, and monitor early and consistently. Done this way, TRT can be both effective and responsibly managed—minimizing transient risks while pursuing durable benefits.

Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional about your specific health questions and before making changes to your medications or treatment plan.

Sources

Ex Vivo TU Conversion and Oral TRT Dosing Accuracy

Posted on by Taurus

Ex Vivo TU Conversion and Oral TRT Dosing Accuracy

Ex vivo conversion of TU to testosterone can inflate lab values after a blood draw, risking dosing errors. With 3–6 hour timing and validated plain tubes, clinics can monitor oral TRT accurately without special supplies.

Estimated reading time: 10 minutes

Key takeaways

  • Ex vivo conversion of testosterone undecanoate (TU) to testosterone (T) after the blood draw can inflate measured T and mislead dosing decisions if not controlled.
  • FDA concerns were resolved with tube/processing validation, PK modeling, and a small adjustment factor enabling accurate monitoring without special collection supplies.
  • A single 3–6 hour post-dose sample (commonly 4–6 hours) using validated plain tubes reliably reflects average exposure for Jatenzo and Tlando titration.
  • NaF/EDTA tubes suppress ex vivo conversion but may under-report T at higher TU levels; labels rely on validated plain-tube methods instead.

Table of contents

  1. Why Oral TRT Monitoring Got Complicated
  2. What the FDA Required—and How It Was Resolved
  3. What the Studies Actually Found
  4. Practical Implications for Oral TRT Monitoring
  5. Safety Context: What Else Gets Monitored
  6. Limitations and Open Questions
  7. Considerations for Clinics and Laboratories
  8. What This Means for Patients on Jatenzo or Tlando
  9. How Taurus Meds Approaches Oral TRT Monitoring
  10. Conclusion
  11. Disclaimer
  12. Sources

Why Oral TRT Monitoring Got Complicated

Oral testosterone undecanoate (TU) products like Jatenzo and Tlando have made testosterone replacement therapy (TRT) more convenient for many men. But they also introduced a technical challenge for labs and clinicians: blood draws can overestimate testosterone if TU in the sample converts to testosterone (T) after the draw. The FDA scrutinized this issue for years. The good news: tube and processing validation now support reliable oral TRT monitoring using a single timed blood draw—without exotic collection supplies—when conducted according to product labeling and validated methods.

This section explains what changed, why it matters for accuracy, and what patients and clinics should understand about timing, tube type, and interpretation.

  • Mechanism: Plasma and serum contain esterases that can cleave TU into T after collection. If this happens in the tube, the assay “sees” more T than was in circulation at draw time.
  • Clinical consequence: Overestimation of serum T can prompt down-titration or maintenance of a subtherapeutic dose.
  • Concentration dependence: Ex vivo conversion is more pronounced when post-dose TU is higher, making timed draws sensitive to handling.

What the FDA Required—and How It Was Resolved

Tlando’s multi-year review history illustrates the issue and its resolution. Between 2016 and 2019, the FDA issued Complete Response letters for Tlando, citing an inability to exclude clinically relevant ex vivo conversion as a source of bias in measured testosterone. This was not about efficacy; it was about ensuring routine lab methods could guide dosing accurately.

Two strands of evidence resolved the concern:

  1. Tube and processing validation

    • Ex vivo TU-to-T conversion is concentration-dependent.
    • NaF (±EDTA) tubes reduced conversion by roughly 30–85% versus plain tubes.
    • At higher TU levels (e.g., >15 ng/mL), NaF tubes produced ~14–30% lower measured T, suggesting under-reporting at clinically relevant concentrations.
    • Cold processing (~4°C) minimized ex vivo conversion across tube types.
  2. PK modeling, simulations, and a small adjustment factor

    • For Jatenzo and Tlando, modeling linked a single timed post-dose T value to 24-hour average exposure (Cavg), the efficacy anchor.
    • The strongest window was 3–6 hours post-dose (often ~4 hours), with ~88–95% concordance with Cavg.
    • A small validated correction (about 3% in some analyses; up to ~3–8% for parameters like Cmax) aligned plain-tube measurements with true exposure.

This evidence enabled Jatenzo’s approval (2019) and Tlando’s subsequent approvals. Plain tubes with validated timing/processing—and a small adjustment—met the FDA’s practicality and accuracy bar.

What the Studies Actually Found

  • Ex vivo conversion is real but manageable. Cooling and timely separation mitigate the effect, which is larger when TU is high.
  • NaF/EDTA tubes reduce conversion but may under-report T when TU concentrations are higher, complicating universal use.
  • Modeling supports a single timed sample. A 3–6 hour post-dose draw correlates well with Cavg for eugonadal targeting.
  • High concordance with Cavg. Analyses for Jatenzo and Tlando reported ~88–95% agreement using the validated timing and plain-tube approach.
  • Phase 3 outcomes aligned. Tlando’s fixed-dose regimen and Jatenzo’s titratable regimen met efficacy targets using these methods.

Caution: Inter-site variability may occur; a site with irregular handling produced outlier Cmax values in one FDA review—underscoring the importance of consistent timing and processing.

Practical Implications for Oral TRT Monitoring

  • A single, timed post-dose sample works. Labels rely on a 3–6 hour post-dose draw (commonly 4–6 hours) to gauge average exposure.
  • Plain tubes are acceptable when used as validated. No exotic tubes are required in routine practice when handling follows validated methods.
  • Why not always use NaF/EDTA? They lessen conversion but can under-report T at higher TU levels; labeling reflects a practical, validated plain-tube approach with a small correction.
  • Timing matters. Drawing too early or too late can misrepresent exposure; the 3–6 hour window is PK-driven.
  • Interpretation guides titration. Clinicians use the timed T value to adjust within approved ranges, aiming for eugonadal exposure while monitoring safety labs.

Safety Context: What Else Gets Monitored

  • Blood pressure: Oral TU products carry a boxed warning for BP increases (often ~3–5 mmHg). Baseline CV risk assessment and on-therapy monitoring are standard.
  • Hematologic changes: Average hematocrit increases (e.g., ~3.2%) occur with TRT. Baseline and periodic checks are recommended.
  • Contraindications and precautions: As with all TRT, observe label-directed warnings (e.g., prostate/breast cancer considerations) and routine safety monitoring.

Limitations and Open Questions

  • Universal adjustment factor: The exact correction may vary across doses, populations, and lab platforms.
  • Real-world performance: Community variability in timing, handling, and assays can influence accuracy.
  • High TU concentrations: The NaF vs. plain-tube differences at very high TU levels warrant ongoing attention.
  • Populations studied: Precision data often come from Phase 1/3 hypogonadal male cohorts; broader generalizability is inferred.

Considerations for Clinics and Laboratories

  • Align the draw with dosing: Schedule testosterone measurement 3–6 hours post-dose per product labeling.
  • Use validated plain tubes: These underpinned efficacy/safety decisions and are practical with proper handling.
  • Emphasize prompt, controlled processing: Cooling and timely separation reduce ex vivo conversion variability.
  • Be alert to outliers: Unexpected values, or deviations in timing/handling, may merit repeat testing.

Consistency in timing and handling—more than tube type alone—drives reliable results.

What This Means for Patients on Jatenzo or Tlando

  • Expect a timed blood draw: Typically a few hours after your dose (not before dosing), unlike some injection/gel protocols.
  • Standard labs are usually fine: Routine supplies and validated plain tubes are typically sufficient.
  • Share details with your lab: Confirm product name and timing so staff coordinate the post-dose window correctly.
  • Stay current on safety labs: Blood pressure checks and periodic hematologic labs remain part of care.

How Taurus Meds Approaches Oral TRT Monitoring

  • We coordinate with labs that understand the 3–6 hour post-dose timing used in labeling.
  • We interpret results alongside symptoms, safety parameters, and consistent lab methods.
  • We titrate within approved strategies to maintain eugonadal exposure while prioritizing safety and practicality.

Our goal: predictable, reproducible monitoring—so dose decisions reflect physiology, not collection artifacts.

Conclusion

Ex vivo conversion of TU to testosterone in blood samples was a legitimate hurdle for oral TRT monitoring. Through multiple FDA review cycles, manufacturers demonstrated that a single, timed post-dose sample collected in plain tubes—paired with validated handling and a small adjustment—accurately reflects average testosterone exposure for Jatenzo and Tlando. This enables practical, clinic-friendly monitoring without sacrificing reliability.

Open questions persist around universal adjustments and real-world workflow variability, but the core message is encouraging: with attention to timing and consistent processing, oral TRT can be monitored accurately enough to guide dosing decisions, while maintaining regular safety surveillance for blood pressure and hematologic effects.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalized recommendations on TRT monitoring and dosing.

Sources

TRT for Men in Their 40s Benefits, Outcomes, and Mid-Term Safety

Posted on by Taurus

TRT for Men in Their 40s Benefits, Outcomes, and Mid-Term Safety

Estimated reading time: 8 minutes

Key takeaways

  • In appropriately selected men 40–49 with confirmed hypogonadism, TRT can improve sexual function, increase lean mass, reduce fat mass, and favorably shift metabolic markers.
  • Mid-term safety (~12–36 months) is generally reassuring for major adverse cardiovascular events, though signals like atrial fibrillation, acute kidney injury, and pulmonary embolism warrant monitoring.
  • Key risks include erythrocytosis (more common with injections), prostate-related findings requiring surveillance, and suppression of fertility while on therapy.
  • Evidence specific to men in their 40s is growing but still leans on broader-age studies; long-term outcomes beyond 5–10 years remain uncertain.
  • TRT is not for “healthy aging” or performance enhancement; diagnosis should pair compatible symptoms with two low early-morning testosterone levels.

Table of contents

  1. Why low T shows up in the 40s
  2. What the 2025 review found for 40–49 year olds
  3. Safety: What mid-term data say
  4. Who may benefit—and who should pause
  5. Practical expectations and timeline
  6. Formulations, delivery, and monitoring nuances
  7. The regulatory landscape in 2025
  8. Open questions for this decade
  9. How Taurus Meds supports informed, cautious care
  10. Conclusion

Why low T shows up in the 40s

Many men in their 40s notice lower libido, softer muscle tone, more central fat, lower energy, and mood changes. For some, these reflect confirmed hypogonadism rather than “normal aging.” Total testosterone declines gradually with age, but not universally. In the 40–49 bracket, about 6–12% of men have low testosterone, often influenced by metabolic factors like obesity, insulin resistance, type 2 diabetes, and obstructive sleep apnea.

Diagnosis matters. Guidelines and trials define clinically significant hypogonadism as compatible symptoms plus two separate early‑morning total testosterone measurements below 300 ng/dL. Without both, benefits are less likely and risks may outweigh gains.

What the 2025 review found for 40–49 year olds

A 2025 narrative review synthesizing age-specific data for men 40–49 summarized consistent benefits across randomized trials and meta-analyses when hypogonadism is clearly established:

  • Sexual function: Improved libido and erectile function were common, especially with baseline testosterone below 300 ng/dL and prominent sexual symptoms.
  • Body composition: Lean mass tended to rise while fat mass declined, with the best results when TRT was paired with nutrition, resistance training, and weight management.
  • Metabolic outcomes: Improvements in insulin sensitivity and reductions in waist circumference were observed; these are additive to lifestyle and, when needed, medications.
  • Bone, mood, vitality: Androgen repletion supports bone health over time; many men report better energy and vitality. Mood improvements are variable and context-dependent.

Bottom line: For properly selected men in their 40s, benefits are real and reproducible, though effect sizes vary.

Safety: What mid-term data say

Mid-term safety is a central question for men early in midlife. Findings from the large randomized, placebo-controlled TRAVERSE program (5,246 men aged 45–80; median follow-up ~33 months) are instructive, including secondary analyses of non-MACE outcomes:

  • MACE: No significant increase in major adverse cardiovascular events versus placebo in the overall population.
  • Non-MACE signals: Numerical increases in atrial fibrillation, acute kidney injury, and pulmonary embolism were observed, warranting judicious selection and routine monitoring.
  • Quality of life: Sexual function and broader QoL improvements were consistent with prior research.

Other key safety considerations:

  • Erythrocytosis: Most common lab issue; more frequent with intramuscular injections than topicals. Manage with dose/formulation adjustments or phlebotomy, guided by routine labs.
  • Prostate: Mid-term data do not show increased prostate cancer risk, but PSA can rise and may unmask pathology; baseline assessment and surveillance are standard.
  • Fertility: Exogenous testosterone suppresses spermatogenesis; men planning children should consider alternatives (e.g., SERMs, gonadotropins).
  • Sleep apnea and fluid: Untreated sleep apnea can worsen; some men experience edema.

For men specifically in their 40s, the mid-term picture is reassuring but not definitive; long-term (>5–10 years) cardiovascular and prostate outcomes need more age-specific data.

Who may benefit—and who should pause

You may be a candidate to discuss TRT if:

  • You have consistent symptoms (e.g., reduced libido, erectile difficulties, decreased morning erections, fatigue, loss of muscle/strength, increased abdominal fat, low mood), and
  • Two separate early‑morning total testosterone levels are below 300 ng/dL under stable health conditions, and
  • Other causes of symptoms (thyroid disease, depression, medication effects, heavy alcohol use, untreated sleep apnea) have been considered.

You may need to pause or think differently if:

  • You are trying to conceive soon.
  • You have uncontrolled cardiovascular disease or a recent major cardiovascular event.
  • You have untreated severe sleep apnea, very high hematocrit, or concerning prostate findings pending evaluation.
  • Your testosterone is borderline/normal and symptoms point elsewhere.

Best outcomes often come from integrated care: endocrine evaluation, cardiometabolic risk reduction, sleep and mental health review, and individualized monitoring.

Practical expectations and timeline

  • Weeks 2–6: Libido may begin improving; some men note better energy, motivation, and sleep.
  • Weeks 6–12: Ongoing gains in erectile function and sexual satisfaction; training capacity and recovery often feel better.
  • Months 3–6: Measurable body composition changes (↑ lean mass, ↓ fat mass), especially with resistance training and nutrition support.
  • Months 6–12+: Continued favorable trends in insulin sensitivity and waist circumference, particularly alongside lifestyle changes.

Expect periodic labs (e.g., hematocrit, PSA) and symptom reviews; dose and formulation adjustments are common to balance benefit and side effects.

Formulations, delivery, and monitoring nuances

  • Topical gels/solutions: Steady levels; daily use; transference risk; generally lower erythrocytosis risk.
  • Intramuscular/subcutaneous injections: Flexible dosing; higher peaks/troughs without careful titration; higher erythrocytosis risk.
  • Other options: Routes and convenience vary as new formulations evolve.

Monitoring themes for men in their 40s:

  • Hematocrit trends and thresholds linked to clotting risk.
  • PSA and prostate symptoms, with urology input as indicated.
  • Cardiometabolic profile: blood pressure, lipids, glucose/insulin sensitivity, weight, and waist circumference.
  • Symptom tracking: sexual function, energy, mood, sleep, and exercise capacity.

The regulatory landscape in 2025

As of late 2025, the FDA continues to center TRT indications on classical hypogonadism, while noting it will consider supplemental applications for idiopathic hypogonadism with specific symptom targets such as low libido. See the agency’s update: FDA announcement on testosterone therapy considerations.

In practice: Clear documentation of symptoms with corroborating low testosterone remains essential; off-label use should be guided by emerging evidence, safety monitoring, and individualized risk–benefit discussions.

Open questions for this decade

  • Long-term safety: More age-specific data beyond 5–10 years for cardiovascular and prostate outcomes are needed.
  • Precision medicine: Can genetics, SHBG, or body composition predict response and risk?
  • Formulation/dosing: Better head-to-head trials to optimize benefit while minimizing erythrocytosis and other adverse events.
  • Metabolic strategy: How TRT compares or combines with GLP‑1 receptor agonists and other weight-centric therapies in men with obesity/metabolic syndrome.
  • Fertility-preserving pathways: Optimal protocols for symptom relief while maintaining or restoring spermatogenesis.

How Taurus Meds supports informed, cautious care

Taurus Meds emphasizes individualized, evidence-based evaluation for men in their 40s considering TRT. We focus on careful symptom assessment, biochemical confirmation, and discussions about goals, risks, fertility, and alternatives. When TRT is appropriate, we integrate monitoring, lifestyle optimization, and dose/formulation choices tailored to your health profile. When it isn’t, we help you pursue other paths to better energy, sexual health, and body composition.

Conclusion

For men in their 40s with confirmed hypogonadism, TRT can meaningfully improve sexual function, lean mass, fat distribution, and metabolic markers—especially when paired with sleep optimization, resistance training, nutrition, and weight management. Mid-term safety data are reassuring regarding major cardiovascular events, but non-MACE signals and known risks like erythrocytosis, prostate considerations, and fertility suppression require careful monitoring. The strongest results occur when diagnostic criteria are met, targets are clear, and clinicians track outcomes and adjust along the way.

Disclaimer

This article is for informational purposes only and does not constitute medical advice. It does not replace professional evaluation, diagnosis, or treatment. Always consult a qualified healthcare professional about your specific situation.

Sources

TRT and Acute Kidney Injury What Recent Safety Reviews Show

Posted on by Taurus

TRT and Acute Kidney Injury What Recent Safety Reviews Show

Estimated reading time: ~10 minutes

Key takeaways

  • A modest AKI signal has emerged in higher-risk men on TRT, with low absolute rates (roughly a 1–2% absolute difference over several years).
  • TRAVERSE and real-world cohorts show elevated AKI risk, while other observational work is neutral—underscoring uncertainty and the value of monitoring.
  • Early therapy (3–6 months), obesity, diabetes, and hypertension appear to mark higher risk; blood pressure and hematocrit are key safety levers.
  • No hydration “threshold” prevents AKI, but steady hydration and avoidance of dehydration during illness, heat, or intense training are prudent.
  • Shared decision-making and a structured safety plan help preserve TRT benefits while managing kidney risk.

Table of contents

  1. Overview: Acute kidney injury signals in TRT users
  2. What the latest evidence shows
  3. How might TRT influence kidney risk?
  4. Who may need closer monitoring?
  5. Practical monitoring for renal safety on TRT
  6. Hydration and lifestyle considerations
  7. Oral vs injectable TRT: Any difference for the kidneys?
  8. What we still don’t know
  9. How Taurus Meds approaches renal safety
  10. Conclusion

Overview: Acute kidney injury signals in TRT users

Testosterone replacement therapy (TRT) is increasingly prescribed for symptomatic hypogonadism, and its cardiovascular safety has been studied intensively. Less discussed—but important for men weighing risks and benefits—is kidney safety. Recent evidence, including secondary outcomes from the TRAVERSE randomized trial and newer real-world analyses, suggests a small increase in acute kidney injury (AKI) among certain TRT users. This article unpacks what that signal means, who it might affect most, and how practical monitoring and hydration habits can support safer therapy.

What the latest evidence shows

Two types of studies inform the current view of TRT kidney injury risk: randomized trial data and observational real-world cohorts.

  • TRAVERSE randomized controlled trial: In men with hypogonadism and high cardiovascular risk, AKI occurred in 2.3% of those assigned to TRT vs 1.5% with placebo (P=0.04). Although AKI was a secondary outcome and the trial was not powered specifically for renal endpoints, the difference was statistically significant and prompted attention to renal safety alongside other non-MACE signals (like atrial fibrillation and pulmonary embolism).
  • Real-world cohort data (Journal of Sexual Medicine, 2025–2026): A multi-year analysis of 4,268 hypogonadal men found AKI in 3.5% of TRT users vs 2.3% of non-users over approximately three years (P=0.018; relative risk 1.53, 95% CI 1.07–2.18). TRT users in this study had more cardiometabolic comorbidity at baseline (e.g., higher rates of obesity and diabetes), which could partly explain the difference but does not fully negate the signal.

Context matters. Absolute AKI rates remained low in both studies, and the observed risk increase translates to a modest absolute difference (around 1–2% over several years in higher-risk men). Notably, some broader observational studies (outside high-risk cohorts) report neutral or slightly lower AKI risk with TRT, highlighting how baseline risk, selection criteria, and confounding can alter findings. Taken together, the data suggest TRT kidney injury risk is small but real in certain populations and warrants routine kidney- and blood-pressure–focused monitoring.

How might TRT influence kidney risk?

Potential contributors to AKI risk on TRT include:

  • Blood pressure effects: Ambulatory blood pressure monitoring in clinical reviews of oral testosterone undecanoate formulations demonstrated average increases in blood pressure. Even small sustained BP rises can increase renal workload, particularly in men with pre-existing hypertension or CKD risk.
  • Erythrocytosis and viscosity: TRT can raise hematocrit. Higher blood viscosity may, in theory, reduce renal microcirculatory reserve during dehydration or acute illness. Hematocrit above 54% is a recognized threshold to pause or adjust therapy.
  • Volume status: Dehydration from illness, heat exposure, or intense training—especially when combined with diuretics or NSAIDs—can precipitate AKI. If TRT also nudges blood pressure or hematocrit upward, this may further narrow the margin for error.
  • Underlying comorbidity: Obesity, diabetes, and hypertension are common in men seeking TRT and independently increase AKI risk. The real-world study found higher rates of these conditions among TRT users, which may amplify vulnerability.
  • Mechanisms still uncertain: There is no consensus on a direct nephrotoxic effect of testosterone at physiologic replacement doses. The signal could reflect hemodynamic changes, susceptibility in at-risk men, or residual confounding in observational designs.

Who may need closer monitoring?

Based on the trials, regulatory reviews, and real-world patterns, closer renal safety monitoring is especially relevant for:

  • Men with obesity (BMI ≥30), diabetes, or hypertension
  • Those with borderline renal function at baseline or a history of AKI
  • Early in therapy (first 3–6 months), when many physiologic adjustments occur
  • Users of medications that influence renal perfusion (e.g., ACE inhibitors/ARBs, diuretics) or nephrotoxic agents (e.g., frequent NSAID use), particularly during illness or dehydration
  • Men on formulations associated with blood pressure increases or men who have rising hematocrit on therapy

None of these factors automatically disqualify someone from TRT, but they raise the value of baseline assessment and scheduled follow-up.

Practical monitoring for renal safety on TRT

While protocols vary, a cautious, patient-centered monitoring approach can help detect issues before they become problems.

  • Before starting:
    • Confirm hypogonadism with appropriate testing and review comorbidities.
    • Baseline labs: serum creatinine and eGFR; hematocrit/hemoglobin; blood pressure assessment. Consider urinalysis if CKD risk is present.
  • Early follow-up:
    • Recheck renal function and blood pressure at approximately 3–6 months after initiation or dose adjustment.
    • Monitor hematocrit; many programs pause or modify therapy if hematocrit exceeds 54%.
  • Ongoing surveillance:
    • Annual kidney function and hematologic monitoring for lower-risk men; more frequent checks if CKD, diabetes, hypertension, or rising hematocrit is present.
    • Encourage home blood pressure tracking, especially for those on oral testosterone undecanoate or with borderline office readings.
  • Red flags prompting clinician contact:
    • A sustained, unexplained rise in creatinine or drop in eGFR compared with baseline
    • New or worsening hypertension, headaches, or edema
    • Symptoms of possible AKI (e.g., reduced urine output, flank pain, severe fatigue), especially during or after acute illness, dehydration, or use of nephrotoxic medications

These steps are not a substitute for individualized medical care; they reflect the themes emphasized in trial findings and regulatory reviews focused on BP and hematologic effects.

Hydration and lifestyle considerations

No trial has established that hydration “prevents” TRT kidney injury, and no evidence-based intake threshold has been defined. Still, basic hydration and recovery habits matter for kidney health, especially in men with comorbidities.

  • Aim for consistent day-to-day hydration; adjust upward during heat, heavy training, fever, or gastrointestinal illness.
  • Discuss sick-day plans with your clinician if you take medications that can affect kidney blood flow (e.g., diuretics, ACE inhibitors/ARBs). Avoiding dehydration plus high-dose NSAIDs during illness is often prudent.
  • Moderate alcohol; minimize unnecessary NSAID use.
  • Support blood pressure control through nutrition, sleep, and activity. Weight reduction in men with obesity can benefit BP, glycemic control, and renal workload—and may improve TRT response.
  • Keep dosing steady and avoid supraphysiologic peaks. Staying within therapeutic ranges helps limit hematocrit rise and blood pressure shifts.

Again, these are general kidney-friendly practices. They complement, but do not replace, lab monitoring and clinician oversight.

Oral vs injectable TRT: Any difference for the kidneys?

Large head-to-head renal safety comparisons between injectable and oral formulations are limited. However:

  • Regulatory reviews for oral testosterone undecanoate approvals emphasized blood pressure increases on ambulatory monitoring and rises in hematocrit. Neither review highlighted a specific AKI signal in phase 3 programs.
  • Because blood pressure and hematocrit can influence renal risk, men on any formulation should have these parameters tracked. For oral TU, BP monitoring deserves special attention given the observed average increases.
  • In the real-world AKI analysis, formulation-specific kidney outcomes were not the primary focus. The overall pattern suggests patient factors (obesity, diabetes, hypertension) may carry as much or more weight than formulation choice.

Bottom line: choose a formulation with your clinician that achieves physiologic replacement and is practical for adherence and monitoring, then follow a structured safety plan.

What we still don’t know

  • Causality and mechanisms: Is the AKI signal driven by BP changes, hematocrit-related viscosity, unmeasured confounding, or a direct renal effect?
  • Timing: Are the first 3–6 months the highest-risk window, and does risk plateau thereafter?
  • Long-term outcomes: How does AKI risk evolve beyond three years, and does TRT influence chronic kidney disease progression differently across risk groups?
  • Prevention strategies: Can tailored hydration, careful NSAID use, and BP optimization measurably reduce AKI risk on TRT, and by how much?
  • Best monitoring cadence: What follow-up schedule maximizes safety while minimizing burden in varied risk profiles?

How Taurus Meds approaches renal safety

  • We start with a thorough baseline evaluation, including renal function, hematocrit, and blood pressure.
  • Early follow-up at 3–6 months helps catch trends in eGFR, creatinine, BP, and hematocrit.
  • We individualize surveillance intensity for men with obesity, diabetes, hypertension, or early CKD.
  • Patients receive practical guidance on hydration, sick-day considerations, and when to contact the care team.
  • We coordinate with primary care and cardiometabolic specialists when needed to align goals and reduce polypharmacy risks.

This approach aims to preserve the benefits of TRT while managing the small but meaningful risk of kidney injury.

Conclusion

The best current evidence suggests a modest increase in AKI among higher-risk men on TRT, with low absolute event rates. TRAVERSE and real-world data align in signaling an elevated risk, while other observational work indicates the story may be more nuanced in broader populations. Until more definitive answers arrive, practical steps—baseline assessment, early and periodic monitoring of renal function, blood pressure, and hematocrit, plus attention to hydration and comorbidities—offer a balanced path forward.

For men considering TRT or already on therapy, the question is not “Is TRT safe for kidneys?” but rather “What is my personal kidney risk, and how will we monitor and manage it?” With structured oversight and shared decision-making, most men can navigate TRT kidney injury concerns thoughtfully and safely.

Disclaimer

This article is for educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional about your specific health circumstances.

Sources

Sleep Apnea and TRT Practical Care for Hypogonadal Men

Posted on by Taurus

Sleep Apnea and TRT Practical Care for Hypogonadal Men

Untreated sleep apnea can lower testosterone and complicate TRT. See when to prioritize CPAP, how to dose conservatively, and what labs and symptoms to monitor.

Estimated reading time: 10 minutes

Key takeaways

  • Untreated OSA can contribute to secondary hypogonadism via intermittent hypoxia and sleep fragmentation.
  • Most guidance prioritizes treating moderate–severe OSA (e.g., CPAP) before initiating TRT.
  • TRT can worsen sleep-disordered breathing in susceptible men, especially with supraphysiologic dosing or early in therapy.
  • CPAP often improves total testosterone and erectile function, sometimes independent of weight loss.
  • OSA and TRT both can raise hematocrit and influence blood pressure—monitor closely and dose conservatively.

Table of contents

  1. Does Sleep Apnea Complicate TRT? Diagnosis and Management in Hypogonadal Men
  2. How Obstructive Sleep Apnea Affects Testosterone
  3. Can TRT Worsen Sleep Apnea?
  4. Sequencing Care: CPAP First, Then Reassess Testosterone
  5. Monitoring Overlaps: Hematocrit, Blood Pressure, and Sleep Quality
  6. Sexual Function: CPAP, TRT, or Both?
  7. Practical Signs That You Should Revisit Your Plan
  8. Special Considerations and Adjacent Levers
  9. How Taurus Meds Approaches TRT in the Context of Sleep Apnea
  10. What We Still Don’t Know (Yet)
  11. Conclusion

Does Sleep Apnea Complicate TRT? Diagnosis and Management in Hypogonadal Men

Many men pursuing testosterone replacement therapy (TRT) also live with undiagnosed or untreated obstructive sleep apnea (OSA). The overlap matters. Untreated OSA can lower testosterone and mimic or worsen hypogonadal symptoms, while TRT may exacerbate sleep-disordered breathing or raise hematocrit, a risk also seen with OSA itself. Understanding this two-way relationship helps set realistic expectations and safer treatment plans.

How Obstructive Sleep Apnea Affects Testosterone

OSA fragments sleep and repeatedly lowers oxygen levels overnight. Both processes are unfavorable for testosterone production, which relies on consolidated sleep and normal hypothalamic–pituitary–gonadal signaling. Across observational studies, apnea severity (e.g., higher apnea–hypopnea index and oxygen desaturation index) correlates with lower total testosterone, even after accounting for BMI.

Why this matters if you have low T:

  • OSA can be a hidden driver of secondary hypogonadism, especially in men with snoring, witnessed apneas, morning headaches, or daytime sleepiness.
  • Treating OSA with continuous positive airway pressure (CPAP) often improves total testosterone and energy, and can modestly improve body composition and sexual function in some men.
  • In several cohorts, CPAP improved testosterone levels independent of weight loss—so it is not only weight change explaining the hormone shift.

If you feel “low T” symptoms plus classic OSA features, the sleep disorder may be part of the root cause.

Can TRT Worsen Sleep Apnea?

The relationship appears bidirectional. Mechanistically, testosterone can influence upper airway muscle tone, ventilatory responses to hypoxia and hypercapnia, and oxygen demand—all of which may worsen sleep-disordered breathing in vulnerable individuals. Observational data suggest TRT users may have a higher incidence of OSA diagnoses over time compared to non-users (one cohort reported 16.5% vs 12.7% at two years). Not all studies agree, and confounding by obesity and comorbidities is common.

Important nuances:

  • Dose and duration matter. Short-term, higher-dose regimens are more likely to aggravate apnea indices than physiologic, steady-state replacement.
  • Not every man on TRT develops or worsens OSA, but new or louder snoring, unrefreshing sleep, morning headaches, or bed-partner reports of pauses in breathing after starting therapy warrant attention.
  • Current guidance typically lists severe, untreated OSA as a contraindication to initiating TRT. European recommendations have softened the stance slightly, focusing on risk assessment and monitoring rather than absolute prohibition, but the principle remains: address significant OSA first.

Sequencing Care: CPAP First, Then Reassess Testosterone

For men with low testosterone levels and suspected or known OSA, a pragmatic sequence often helps:

  1. Screen for OSA if low T is present—especially in men with snoring, obesity, resistant hypertension, or daytime sleepiness. When suspicion is high, formal sleep testing (e.g., polysomnography or home sleep apnea testing as appropriate) is usually warranted.
  2. Prioritize OSA treatment if moderate-to-severe disease is found. CPAP is the mainstay, alongside weight management and addressing nasal or airway contributors when relevant.
  3. Reassess symptoms and testosterone after OSA therapy is established. Many men experience improved energy, libido, and even testosterone levels on effective CPAP.
  4. If hypogonadism persists (confirmed by morning total testosterone, ideally on two separate days with appropriate lab technique), consider TRT with careful oversight.
  5. If TRT is started, continue OSA therapy without interruption, and monitor for changes in sleep quality, snoring, and oxygenation. Adjust TRT dosing to maintain physiologic targets, not supraphysiologic peaks.

Why this order? It reduces the chance of TRT aggravating untreated sleep-disordered breathing, and it may spare some men from needing TRT at all. It also provides a clearer baseline for monitoring hematocrit and blood pressure once TRT begins.

Monitoring Overlaps: Hematocrit, Blood Pressure, and Sleep Quality

Hematocrit and erythrocytosis:

  • Both OSA (via chronic hypoxia) and TRT can raise hematocrit. Clinical trials suggest TRT increases hematocrit by roughly 3% on average, but individual responses vary widely.
  • Many clinicians monitor hematocrit at baseline, again at 3–6 months after starting or changing dose, and then periodically. Men with OSA or prior high hematocrit may need closer follow-up.
  • If hematocrit rises substantially (for example, approaching or exceeding ~52%), clinicians often consider dose adjustments, addressing OSA adherence, evaluating for other hypoxic drivers (e.g., altitude, smoking), or therapeutic phlebotomy.

Blood pressure:

  • OSA commonly contributes to hypertension.
  • In February 2025, the FDA removed the boxed warning on major adverse cardiac events from testosterone labeling but added a class-wide blood pressure warning based on ambulatory monitoring data. Practically, this means blood pressure deserves routine attention before and during TRT.
  • Expect your care team to check and manage blood pressure throughout therapy.

Sleep quality and hypoxia:

  • If TRT is introduced, watch for new or worsening snoring, gasping, nocturia, nonrestorative sleep, or morning headaches.
  • Bed-partner observations can be invaluable. Consumer wearables and smartphone oximetry are not diagnostic but can prompt timely conversations if trends worsen.
  • If CPAP adherence slips, apnea can worsen—and so can hematocrit and blood pressure. Work with your sleep team on mask fit and comfort.

Sexual Function: CPAP, TRT, or Both?

  • Erectile dysfunction (ED) and low libido are common in both OSA and hypogonadism. CPAP alone improves ED in a substantial share of men with OSA, even when testosterone does not rise meaningfully.
  • In men with persistent hypogonadism after OSA treatment, combining CPAP and TRT may further improve sexual function compared to either alone.
  • If your primary goal is sexual health, optimizing sleep first often pays dividends and may clarify how much additional benefit TRT can offer.

Practical Signs That You Should Revisit Your Plan

Whether you’re considering TRT or already on therapy, bring these changes to your clinician’s attention:

  • New or louder snoring, witnessed apneas, or choking/gasping at night
  • Morning headaches, unrefreshing sleep, or daytime sleepiness that starts or worsens after TRT
  • Rising hematocrit on routine labs, especially alongside snoring or high-altitude exposure
  • Blood pressure creeping up after starting TRT
  • Poor CPAP comfort or adherence

Small course corrections—optimizing CPAP, adjusting TRT dose or formulation, tackling nasal congestion, or reevaluating sleep severity—can restore balance.

Special Considerations and Adjacent Levers

  • Weight management: Many men with “low T + OSA” also have central obesity. Sustained weight loss improves both sleep apnea severity and testosterone biology. Emerging anti-obesity medications (e.g., GLP-1–based therapies) may help reduce AHI and improve metabolic health, though long-term data on testosterone and sleep outcomes remain limited.
  • Formulation and dosing: Steady, physiologic replacement is the goal. Short-acting formulations or regimens that avoid large peaks may be preferable if apnea worsens with higher serum swings. Personalization and monitoring matter more than brand or route.
  • Lifestyle and environment: Alcohol near bedtime and sedatives can relax airway muscles and worsen OSA. High altitude may drive hypoxia and erythrocytosis; smokers have additive risks. Addressing these factors can simplify TRT management.
  • Age and comorbidity: Late-onset hypogonadism often overlaps with OSA, visceral adiposity, insulin resistance, and hypertension. Multifaceted care tends to outperform single-issue fixes.

How Taurus Meds Approaches TRT in the Context of Sleep Apnea

  • We screen for OSA risk before and after starting TRT and coordinate with sleep specialists when a formal evaluation is appropriate.
  • We support CPAP-first sequencing when OSA is moderate to severe, then reassess hormonal status and symptoms.
  • We aim for physiologic testosterone targets and use monitoring plans that include hematocrit, blood pressure, and symptom check-ins.
  • When lab results or symptoms shift, we adjust dosing or timing and collaborate with your sleep team to keep therapy safe and effective.

The goal is not just “higher T,” but better health, energy, and sexual function—with sleep and cardiometabolic risk in view.

What We Still Don’t Know (Yet)

  • The best sequencing strategy for mild OSA with borderline low T (e.g., simultaneous CPAP and low-dose TRT vs. stepwise)
  • How different TRT formulations and dosing schedules affect apnea metrics over years, not months
  • Long-term rates of erythrocytosis and cardiovascular outcomes in men with OSA on TRT
  • The full impact of modern weight-loss therapies on the OSA–hypogonadism axis

As new data emerge, recommendations may evolve from caution-based to more individualized risk profiles.

Conclusion

TRT and sleep apnea intersect in ways that can either help or hinder your goals. Untreated OSA can depress testosterone and mimic hypogonadal symptoms, and TRT—especially at higher peaks—may aggravate sleep-disordered breathing in some men. The safest path for many is straightforward: identify and treat OSA first, then personalize TRT if hypogonadism persists, with vigilant monitoring of hematocrit, blood pressure, and sleep quality. With this approach, many men experience meaningful gains in energy, sexual function, and overall well-being—without losing ground on sleep or safety.

Disclaimer

This article is for educational purposes only and is not a substitute for personalized medical advice. Do not start, stop, or change any medication or device (including CPAP) without consulting a qualified clinician.

Sources

Oral TRT Prolactin Monitoring Under the Tlando Label

Posted on by Taurus

Oral TRT Prolactin Monitoring Under the Tlando Label

Estimated reading time: 8 minutes

Key takeaways

  • The FDA-approved Tlando label instructs clinicians to check serum prolactin before initiation and again 3–4 months after starting; discontinue if prolactin remains elevated after starting.
  • Short-term data show occasional, modest prolactin rises (about 6.3% of participants; mean ~+7.0 ng/mL in a 24-day study), prompting label-level monitoring guidance.
  • Injectable TRT products generally do not include a similar prolactin monitoring requirement in their labels.
  • Monitoring still centers on testosterone levels, hematocrit, blood pressure, and prostate parameters; prolactin is a formulation-specific add-on for Tlando.
  • Plan baseline and 3–4 month labs with your clinician to align therapy and follow-up with label guidance.

Table of contents

  1. Why Prolactin Is Entering the TRT Conversation Now
  2. What the FDA Required After Tlando’s Approval
  3. What the Clinical Data Show So Far
  4. How Monitoring Differs for Oral TRT vs. Injectables
  5. Practical Implications for Patients Considering Oral TRT
  6. Open Questions: HPA Axis and Long-Term Safety
  7. How Taurus Meds Thinks About “Testosterone Prolactin Levels” in Care Plans
  8. Conclusion

TRT Monitoring Protocols for Prolactin in Oral Formulations: What Tlando’s FDA Label Means for Patients

Oral testosterone undecanoate has changed how some men approach testosterone replacement therapy (TRT). But Tlando (oral testosterone undecanoate), approved by the FDA in 2022, arrives with a unique monitoring note that often surprises patients and clinicians alike: check serum prolactin before starting and again 3–4 months after initiation, with discontinuation advised if prolactin remains elevated. That language appears in the FDA-approved prescribing information and is not emphasized in most injectable TRT protocols. This article unpacks what that means in practice, how we got here, and what open questions remain for oral TRT users.

Why Prolactin Is Entering the TRT Conversation Now

Prolactin is a pituitary hormone. Outside of specific clinical contexts, it is not routinely emphasized in standard TRT monitoring. That changed for oral testosterone undecanoate with Tlando, whose FDA label explicitly instructs clinicians to check serum prolactin levels before starting therapy and again after 3–4 months of treatment, and to discontinue if levels remain elevated after initiation.

This labeling followed clinical trial findings that suggested an inconsistent but real signal for prolactin increases during short-term exposure. The FDA addressed the signal in the Warnings and Precautions section of Tlando’s label and retained that language in a subsequent 2025 label update. This is a formulation-specific requirement, not a universal standard across all TRT modalities. For men exploring oral TRT, that means prolactin is a practical monitoring step that may influence whether you remain on a given regimen.

What the FDA Required After Tlando’s Approval

When Tlando (NDA 208088) was approved in 2022, the FDA mandated several postmarketing studies under Section 505(o)(3) of the FDCA. Among those were studies related to potential hypothalamic–pituitary–adrenal (HPA) axis effects, reflecting the agency’s interest in endocrine consequences beyond serum testosterone.

At the same time, the FDA’s review flagged increased prolactin as a safety signal. Rather than requiring a separate postmarketing study solely devoted to prolactin, the agency incorporated a clear action into the label: screen prolactin before initiation, reassess 3–4 months into therapy, and discontinue if it remains elevated after starting. A 2025 label update retained this approach, providing a defined pathway for surveillance and action while longer-term data mature.

What the Clinical Data Show So Far

  • In a 24-day clinical study of Tlando, 6.3% (6 of 95) of participants experienced increases in serum prolactin, with a mean change of approximately +7.0 ng/mL from baseline.
  • A longer 4-month study did not reassess prolactin after screening, so longitudinal changes beyond the initial period are not well characterized in the pivotal data.
  • The FDA considered the prolactin findings inconsistent but noteworthy enough to address through labeling.

Two caveats matter for interpretation:

  • The label does not define a numeric threshold for “elevated” prolactin. Reference intervals vary across labs, so the decision to stop therapy hinges on clinician judgment and patient-specific context.
  • The label cautions against use in patients with prolactin-dependent tumors, underscoring the potential clinical weight of prolactin changes in certain conditions.

Bottom line: the data suggest occasional, modest increases in prolactin with Tlando in the short term, with an FDA-mandated monitoring protocol. The clinical significance of small, asymptomatic increases remains uncertain, and longer-term data are still developing.

How Monitoring Differs for Oral TRT vs. Injectables

Most TRT programs, whether topical or injectable, focus on:

  • Achieving physiologic testosterone levels and rechecking after initiation or dose changes
  • Watching hematocrit/hemoglobin to reduce the risk of erythrocytosis
  • Checking blood pressure and cardiovascular risk factors
  • Assessing prostate health parameters as clinically indicated

For Tlando specifically, the label highlights:

  • Serum testosterone: measure about 3–4 weeks after starting to ensure levels fall within the target range (the Tlando label uses a window of approximately 300–1080 ng/dL).
  • Serum prolactin: check prior to initiation and again 3–4 months into therapy; discontinuation is advised if prolactin remains elevated after starting.

Injectable testosterone products generally do not include an FDA-labeled requirement to monitor prolactin in the same way. That difference does not make injectables universally simpler or risk-free—it just means prolactin is not a labeled focus. Regardless of modality, ongoing assessment of hematocrit and cardiovascular risk is core to responsible TRT care.

Practical Implications for Patients Considering Oral TRT

  • Baseline labs with intention: If prolactin will inform whether you start or continue Tlando, plan the test before initiation. Ask how “elevated” will be defined within your lab’s reference interval and clinical context.
  • The 3–4 month checkpoint: Put a date on the calendar for both testosterone and prolactin checks. Clarify in advance what will happen if prolactin is elevated—repeat testing, additional evaluation, a pause, or a switch in modality.
  • Interpretation matters: Small increases may be clinically irrelevant; persistent or marked elevations may prompt action. With no absolute cut-off in the label, real-world decisions rely on clinician judgment and your overall health picture.
  • The monitoring trade-off: Some patients prefer oral formulations to avoid injections; others prioritize fewer lab-specific requirements. Understanding how prolactin fits into follow-up can clarify your choice.
  • Dosing context: Tlando is administered 225 mg twice daily with food. This can influence adherence and lab timing; discuss how and when to draw labs relative to dosing and meals.

Open Questions: HPA Axis and Long-Term Safety

The FDA’s postmarketing requirements for Tlando include studies examining potential HPA axis effects. While prolactin is related to the pituitary, the HPA axis covers a broader endocrine system. These commitments reflect interest in endocrine ripple effects of oral testosterone undecanoate beyond testosterone itself.

Key uncertainties to watch:

  • Do oral formulations uniquely affect prolactin compared with injectables?
  • What is the long-term trajectory of prolactin changes beyond a few months of therapy?
  • Which patients, if any, are more prone to sustained prolactin elevations on oral TU?
  • Do elevations remain subclinical or translate into meaningful symptoms or risks in specific subgroups?

As evidence from real-world use and postmarketing work grows, labels could evolve. For now, the prolactin language remains in place and provides concrete guidance for early monitoring.

How Taurus Meds Thinks About “Testosterone Prolactin Levels” in Care Plans

In practice, the label’s direction translates into a simple, time-bound check for oral TU users: screen prolactin at baseline, and reassess after 3–4 months. That’s a manageable addition to the standard testosterone, hematocrit, blood pressure, and prostate monitoring you and your clinician might already be doing.

For men deciding between oral and injectable TRT, the difference is more about coordination than complexity. If you value oral dosing, plan for the extra prolactin data point. If minimizing lab variability is your priority, injectables may feel more familiar. Either path benefits from a structured lab schedule and clear follow-up conversations.

Taurus Meds supports patients in building these schedules, aligning tests with label guidance, and coordinating with clinicians so that therapy decisions are made with the right information at the right time.

Conclusion

Oral testosterone undecanoate via Tlando introduced a specific, FDA-labeled expectation: monitor serum prolactin before starting, then again 3–4 months into therapy, and discontinue if levels remain elevated after initiation. The evidence behind that instruction is limited and somewhat inconsistent, but the label treats the signal seriously enough to structure care around it.

Injectable TRT modalities do not share this prolactin requirement, which may factor into treatment selection for some men. Regardless of the route, a careful monitoring plan remains essential: track testosterone levels, hematocrit, cardiovascular parameters, and clinician-directed prostate assessments. The right regimen is the one that aligns with your health status, preferences, and ability to engage with monitoring.

As postmarketing studies mature—particularly those related to the HPA axis—expect the evidence base to grow. For now, the safest path is to follow the label, recognize uncertainty where it exists, and make shared decisions with your care team.

Disclaimer

This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication or monitoring plan without consulting a qualified healthcare professional.

Sources

TRT in Older Obese Men LITROS Trial Findings on Function and Body Composition

Posted on by Taurus

TRT in Older Obese Men LITROS Trial Findings on Function and Body Composition

Estimated reading time: 9 minutes

Key takeaways

  • In a 26-week program of intensive diet and supervised exercise, TRT did not add to overall physical performance test scores but helped preserve lean mass and hip BMD.
  • TRT modestly improved VO₂peak and showed signals for cognitive benefit; gains tracked with changes in fitness, strength, and hormones.
  • Metabolomic data suggest TRT restores muscle glycolytic capacity, supporting metabolic flexibility during weight loss.
  • Both TRT and placebo groups improved triglycerides and metabolic syndrome scores with weight loss; TRT showed additional metabolic flexibility signals.
  • Findings are from a small, frail cohort over 26 weeks; long-term safety and durability remain uncertain.

Table of contents

  1. The LITROS Trial at a Glance
  2. What Did TRT Add Beyond Lifestyle?
  3. Mechanism: Restoring Glycolysis and Metabolic Flexibility
  4. Cognitive Outcomes
  5. Why No Extra Boost in Physical Performance Tests?
  6. Safety and Limitations
  7. Practical Considerations
  8. Who Might Be a Candidate?
  9. Open Questions
  10. Bottom Line

Older men with obesity and low testosterone often face a dilemma: how to lose weight without accelerating muscle and bone loss. The LITROS trial (NCT02367105) tested a pragmatic idea—pair medically guided weight loss and supervised exercise with testosterone replacement therapy (TRT)—to see whether TRT could protect lean mass and bone while improving other aging-related outcomes. The results are nuanced and clinically relevant for older obese men considering TRT as part of a structured program.

The LITROS Trial at a Glance

  • Who: 83 men aged 65+ with obesity (BMI ≥30 kg/m²), low testosterone (<10.4 nmol/L), and reduced function (Physical Performance Test ≤31)—a frail population.
  • Design: 26-week, double-blind, placebo-controlled trial of testosterone vs. placebo. All participants received intensive lifestyle intervention: diet targeting ~10% weight loss plus supervised aerobic and resistance training.
  • Goal: Determine whether adding TRT to optimized lifestyle meaningfully improves function, body composition, bone health, metabolism, and cognition in frail, hypogonadal, obese older men.

This design isolates what TRT adds when lifestyle is already optimized—mirroring real-world goals for losing weight without worsening sarcopenia or bone loss.

What Did TRT Add Beyond Lifestyle?

Lifestyle change drove clear improvements in both groups. The incremental effects of TRT were selective but meaningful.

  • Lean body mass: TRT attenuated loss (about −2% vs. −3% with placebo; P = 0.01), reducing sarcopenia risk during weight loss.
  • Thigh muscle volume: Smaller decline with TRT (about −2% vs. −4%; P = 0.04), potentially preserving strength reserve.
  • Hip bone mineral density: Shift from loss to preservation (+0.5% with TRT vs. −1.1% with placebo; P = 0.003).
  • Aerobic capacity (VO₂peak): Both groups improved; TRT produced a greater increase—an additive cardiorespiratory fitness effect.
  • Physical Performance Test (PPT): Similar improvements in both groups; no added composite functional gain with TRT at 26 weeks.
  • Metabolism: Triglycerides and metabolic syndrome scores improved with weight loss in both groups; TRT showed additional signals of metabolic flexibility.

Clinically, TRT functioned as a protective adjunct during intensive weight loss and training—helping keep muscle and bone “on board” while nudging aerobic conditioning.

Mechanism: Restoring Glycolysis and Metabolic Flexibility

A metabolomic substudy of LITROS found that TRT appeared to reprogram skeletal muscle toward greater glycolytic capacity—the ability to quickly generate energy from glucose—crucial during caloric restriction and training.

  • Glycolysis was the primary pathway consistently restored at six months in the TRT group.
  • This aligns with preserved lean mass and thigh muscle volume and may help explain the VO₂peak advantage.
  • The data suggest enhanced metabolic flexibility with TRT, supporting more adaptive responses to diet and exercise.

These insights clarify how TRT may counter weight loss–induced catabolism; whether adaptations persist after stopping TRT is unknown.

Cognitive Outcomes

  • Global cognition improved more with TRT than with lifestyle alone.
  • Predictors of cognitive gains included changes in VO₂peak, muscle strength, total testosterone, and luteinizing hormone—suggesting brain benefits tracked with systemic fitness and hormonal changes.

Cognitive outcomes were secondary and not powered for domain-specific effects after multiple-comparison adjustment, but the signal toward benefit in a structured program is noteworthy.

Why No Extra Boost in Physical Performance Tests?

  • Strong lifestyle effect: Both groups lost ~9% body weight and improved function; short-term floor/ceiling effects can obscure incremental gains.
  • Composite metric limits: PPT aggregates domains (walking, balance, transfers) that may respond more to practice or weight loss than to anabolic signals over six months.
  • Time horizon: Mechanistic advantages (glycolysis, lean mass, bone) may translate to longer-term resilience not captured at 26 weeks.

Safety and Limitations

  • Short duration, small size: 26 weeks; n=83. Durability after discontinuation is unknown.
  • Specific population: Predominantly male Veterans, 65+, obese, hypogonadal, frail—generalizability is limited.
  • Context matters: All participants pursued significant caloric restriction and supervised exercise; effects outside this setting are unclear.
  • Hard outcomes unassessed: Not powered for cardiovascular events, fractures, or prostate outcomes.
  • Mechanistic subset: Muscle metabolomics were performed in a subset; representativeness is uncertain.

Regulatory note: In the U.S., TRT approvals rely on achieving physiologic testosterone levels, not on demonstrated outcome improvements. LITROS provides investigator-driven outcome data for a specific population.

Practical Considerations

  • Lifestyle is foundational: Diet and supervised training drove most functional gains; view TRT (when indicated) as an adjunct to protect lean mass and bone and support aerobic capacity.
  • Expect selective benefits: Don’t expect large added improvements in everyday performance tests over six months; clearest TRT effects were on lean/thigh muscle, hip BMD, and modest VO₂peak gains.
  • Cognition tracks fitness: Cognitive improvements moved with aerobic fitness, strength, and normalized hormones.
  • Monitoring is essential: TRT requires labs and follow-up; optimal dosing and long-term risk–benefit remain open questions.
  • Individual variability: Responses differ; metabolomic data hint at potential “responders,” but prediction is not yet possible.
  • Time horizon: Six months is short in geriatrics; decisions should align with long-term goals and comorbidities.

Who Might Be a Candidate?

  • Men aged 65+ with confirmed clinical hypogonadism
  • Obesity and functional limitations consistent with frailty
  • Capacity and motivation for a structured weight loss and supervised exercise program for at least six months

Findings may not translate to non-frail older men, those unable to engage in structured lifestyle programs, or younger populations. Shared decision-making with a qualified clinician is essential.

Open Questions

  • Durability: Do muscle, bone, metabolic, and cognitive benefits persist beyond six months or require ongoing therapy/training?
  • Safety at scale: What are long-term cardiovascular, prostate, and thromboembolic risks/benefits in this high-risk population?
  • Dose optimization: Could lower doses achieve similar protection with fewer risks?
  • Generalizability: Would results replicate in more diverse, non-Veteran, or non-frail cohorts?
  • Mechanistic markers: Can glycolytic “responders” be identified to personalize therapy?
  • Value: Is adjunctive TRT cost-effective relative to monitoring and medication burden?

Bottom Line

For older obese men pursuing intensive, medically guided weight loss and supervised training, LITROS offers a measured message. Lifestyle change is the engine of improved physical performance. Adding TRT did not further raise composite performance scores over six months—but it did preserve lean muscle and hip bone density, modestly improved VO₂peak, supported metabolic flexibility via renewed glycolysis, and showed signals for cognitive benefit. These selective effects are relevant for frail seniors aiming to lose weight without sacrificing muscle and bone.

The data are promising yet preliminary: the trial was short, small, and not powered for hard safety outcomes. If you fit the LITROS profile, discuss goals, risks, and the commitment required for structured lifestyle change with your clinician.

Disclaimer

This article is for informational purposes only and is not medical advice. It does not diagnose, treat, or recommend any therapy. Decisions about testosterone therapy should be made with a qualified healthcare professional who can assess your individual situation.

Sources

Oral Testosterone Undecanoate Shows No Liver Harm Over Two Years

Posted on by Taurus

Oral Testosterone Undecanoate Shows No Liver Harm Over Two Years

Estimated reading time: 8 minutes

Key takeaways

  • Two-year follow-up of oral testosterone undecanoate (TU; Jatenzo) in hypogonadal men showed no clinically meaningful liver toxicity and stable liver function tests.
  • Safety signals (PSA, hematocrit, HDL reduction, and modest blood pressure rise) were consistent with other TRT options like injections and gels.
  • TU is absorbed via the lymphatic system, avoiding first-pass hepatic metabolism that contributed to liver risks with older oral androgens.
  • Evidence is reassuring but limited by open-label design, small sample size (n=86 at 2 years), and follow-up capped at two years.
  • Monitoring for hematocrit, PSA, blood pressure, and lipids remains standard for men on any TRT regimen.

Table of contents

  1. Why “Oral Testosterone” Once Meant Liver Worries
  2. What Is Oral Testosterone Undecanoate (Jatenzo) and How It Differs
  3. The 2-Year Safety Data at a Glance
  4. What This Means for “Oral TRT Liver Damage”
  5. Other Safety Considerations: What to Watch
  6. Practical Implications for Patients Considering Jatenzo
  7. Limitations of the Evidence and Open Questions
  8. How Oral TU Fits Among TRT Options
  9. Conclusion

Oral TU Liver Safety: 2-Year Data Confirms No Hepatotoxicity vs Older Forms

Oral testosterone therapy has long carried a stigma around liver risk, largely due to experiences with older formulations. The recent 2-year data on oral testosterone undecanoate (TU; brand name Jatenzo) offers a very different picture: maintenance of normal testosterone levels with no evidence of hepatotoxicity in hypogonadal men. Below we break down what changed, what the evidence shows, and what it means if you’re weighing oral TRT against injections or gels.

Why “Oral Testosterone” Once Meant Liver Worries

For years, “oral testosterone” was practically synonymous with “liver risk.” That reputation was earned by alkylated oral androgens such as methyltestosterone, which were historically linked to hepatotoxicity. Those older molecules undergo significant first-pass metabolism in the liver and have been associated with adverse hepatic outcomes.

Oral testosterone undecanoate (TU) is a fundamentally different approach. Rather than pushing a molecule through the liver to achieve active levels, TU leverages lymphatic absorption to bypass first-pass hepatic metabolism. The clinical question has been whether this mechanism translates into real-world liver safety. Two-year data now provide a more confident answer.

What Is Oral Testosterone Undecanoate (Jatenzo) and How It Differs

  • FDA timeline: Jatenzo (oral TU) received FDA approval in March 2019 and became commercially available in early 2020.
  • Absorption: TU is delivered as an ester that is preferentially absorbed via the intestinal lymphatic system, aiming to reduce first-pass liver exposure.
  • Clinical positioning: It offers a needle-free option that avoids the transfer risk of gels. For many men who dislike injections or find transdermal adherence challenging, oral TU provides a practical alternative.

Importantly for men worried about oral TRT liver damage, the clinical trials and the two-year extension study did not show clinically meaningful changes in liver function tests (LFTs).

The 2-Year Safety Data at a Glance

A 2-year open-label extension followed 86 hypogonadal men who continued on oral TU after an initial year of therapy. The results are notable for both efficacy and safety:

  • Testosterone levels: Men maintained eugonadal (normal) serum testosterone throughout the study period.
  • Liver function: No clinically significant changes were observed in ALT, AST, alkaline phosphatase, or bilirubin over the 2-year period. One participant had a transient ALT elevation to more than 4 times the upper limit of normal around Day 270, which normalized by Day 290 without ongoing liver issues.
  • Prostate and hematologic signals: Small, statistically significant increases in prostate-specific antigen (PSA) and hematocrit were observed—changes consistent with what’s seen across injectable and transdermal TRT.
  • Lipids and blood pressure: Minimal LDL impact was reported, with a decrease in HDL cholesterol that is typical of TRT. Average systolic blood pressure rose modestly (on the order of a few millimeters of mercury).
  • Overall: The safety profile of oral TU tracked closely with non-oral TRT options and did not show the hepatotoxicity historically associated with older oral androgens.

These findings echo earlier trial data showing stable LFTs with oral TU and support the idea that TU’s lymphatic absorption avoids the liver strain that prompted concern with prior oral agents.

What This Means for “Oral TRT Liver Damage”

If you’re searching “oral TRT liver damage,” you’re likely trying to separate past concerns from current options. The key takeaway is that oral TU (Jatenzo) does not behave like older alkylated oral androgens with respect to the liver. Over two years of follow-up in hypogonadal men:

  • No signal of clinically meaningful hepatotoxicity was seen.
  • Routine lab monitoring did not show problematic trends in liver enzymes or bilirubin.
  • A single, short-lived ALT spike did not translate to broader safety concerns.

While any medication can affect individuals differently, the best available clinical evidence suggests that oral TU’s design—bypassing first-pass hepatic metabolism—largely decouples modern oral TRT from the historical liver damage narrative.

Other Safety Considerations: What to Watch

Oral TU’s liver profile is encouraging, but TRT monitoring remains important regardless of delivery method. The signals below are expected class effects and are reflected in oral TU data and labeling:

  • Hematocrit: TRT can increase red blood cell mass. Clinicians routinely track hematocrit and may adjust or pause therapy if levels become too high.
  • PSA and prostate health: Small increases in PSA can occur; monitoring and clinical context matter, especially for men with known prostate risks.
  • Blood pressure: Average systolic blood pressure increases of roughly 3–6 mmHg have been observed. Men with existing hypertension should have blood pressure routinely assessed.
  • Lipids: Some reduction in HDL is typical with TRT.
  • Indication: Like other testosterone products, oral TU is indicated for men with confirmed hypogonadism; it is not approved for age-related testosterone decline without a clear deficiency diagnosis.

These are not reasons to avoid therapy outright; they are part of the risk-benefit calculus that clinicians use to guide safe, individualized TRT.

Practical Implications for Patients Considering Jatenzo

  • Convenience and adherence: Oral TU offers a needle-free route and avoids gel transfer risk to partners or children. For some men, daily oral dosing improves adherence; others may prefer less frequent injection schedules.
  • Monitoring cadence: As with any TRT, expect baseline labs and periodic follow-up for hematocrit, PSA, lipids, and blood pressure. The 2-year data support that these parameters typically move in the same direction as with non-oral TRT.
  • Liver reassurance: For men specifically concerned about oral testosterone and the liver, the available two-year evidence is reassuring and materially different from experiences with older oral agents.
  • Individual variability: Dosing and response can vary. Maintaining eugonadal levels is the goal; clinicians may adjust dosing based on serum testosterone and side-effect profile.
  • Lifestyle and comorbidities: Pre-existing cardiovascular risk, sleep apnea, or prostate history may shape the choice and monitoring plan. The absence of hepatotoxicity does not eliminate broader TRT considerations.
  • Access and support: Coordinated care—including lab scheduling, medication management, and clear follow-up plans—helps sustain both efficacy and safety over time. At Taurus Meds, we focus on providing structured support so patients and clinicians can track progress and make informed decisions.

Limitations of the Evidence and Open Questions

The two-year data on Jatenzo are meaningful, but not definitive for all questions men might have about long-term safety:

  • Study design and size: The extension was open-label and industry-supported, with 86 men completing two years. While informative, it’s not a large, blinded outcomes trial.
  • Duration: Data beyond two years are limited. Longer follow-up will be important for understanding cardiovascular and prostate outcomes over time.
  • Comparative effectiveness: Head-to-head trials versus other modern TRT formulations could clarify differences in adherence, metabolic effects, and patient-reported outcomes.
  • Real-world use: Adherence patterns and variability in absorption outside of trial settings merit ongoing study, including how different oral TU products perform across diverse patient populations.

For now, the best reading of the evidence is that oral TU delivers the expected benefits of TRT with a safety profile consistent with non-oral options—and without the liver toxicity shadow that accompanied earlier oral androgens.

How Oral TU Fits Among TRT Options

  • Injections: Offer predictable testosterone exposure with dosing every 1–2 weeks (or longer with some esters). Some men prefer fewer dosing events; others dislike needles or experience peak–trough swings.
  • Transdermals: Avoid needles and allow daily dosing, but require skin precautions to prevent transfer and may cause local irritation.
  • Oral TU: Provides daily oral dosing without first-pass liver metabolism. The two-year data support its liver safety and expected TRT class effects.

The “right” option depends on confirmation of hypogonadism, personal preferences, lifestyle, tolerance, and ongoing lab and clinical findings. It’s reasonable to consider oral TU if you want a needle-free route and are reassured by the emerging liver safety profile.

Conclusion

Oral TU (Jatenzo) represents a significant shift in how we think about oral testosterone. The two-year extension data in hypogonadal men show no evidence of hepatotoxicity, with liver function remaining stable and overall safety tracking closely with injections and gels. While monitoring for hematocrit, PSA, blood pressure, and lipids remains standard, the long-standing association between “oral TRT” and liver damage does not reflect what we see with TU.

As with all TRT decisions, individualized assessment and thoughtful follow-up matter. The current evidence offers men a practical, needle-free option that appears to sidestep the liver risks of older oral androgens—an important development for patient choice and comfort.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any questions you have regarding a medical condition or therapy.

Sources